Foresite Capital Management VI LLC
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), Foresite Capital Management VI LLC reported 17 stock positions worth $460.3 million. Its top holding was CG Oncology (CGON) at 32.7% of the portfolio, followed by Alumis (ALMS, 20.3%) and Centessa Pharmaceuticals (CNTA, 11.8%). Compared with Q4 2025, it opened 7 new positions, sold out of 2, added to 4 and reduced 1. The biggest buy was Corvus Pharmaceuticals (CRVS, shares +33%) and the biggest sale an exit from Rapt Therapeutics (RAPT).
- Most Recent 13F
- Q2 2026
- Location
- WEST HOLLYWOOD, CA
- CIK
- 0002013341
- Portfolio Value
- $460.3M (Q1 2026)
- SEC Filing
- 0001104659-26-062467 ↗ filed May 15, 2026
Holdings Value
Holdings 17 stocks · $460.3M
| CGON CG Oncology Inc. | 32.67% | 2,221,474 | $150.3M | No change |
| ALMS Alumis Inc. | 20.33% | 4,247,670 | $93.6M | No change |
| CNTA Centessa Pharmaceuticals Ltd. | 11.77% | 1,364,019 | $54.2M | No change |
| CRVS Corvus Pharmaceuticals Inc. | 5.82% | 1,831,233 | $26.8M | Add +32.6% |
| DNLI Denali Therapeutics Inc. | 5.05% | 1,209,971 | $23.2M | Add +21.0% |
| AGIO Agios Pharmaceuticals Inc. | 3.86% | 525,000 | $17.8M | Reduce -0.9% |
| VSTM Verastem Inc. | 3.62% | 3,146,631 | $16.7M | Add +0.4% |
| KYMR Kymera Therapeutics Inc. | 2.65% | 146,332 | $12.2M | No change |
| NERV Minerva Neurosciences Inc. | 2.60% | 1,986,600 | $12.0M | New |
| CLDX Celldex Therapeutics Inc. | 2.18% | 315,913 | $10.0M | New |
| ATAI Ataibeckley Inc. | 2.12% | 2,750,000 | $9.7M | No change |
| HNGE Hinge Health Inc. Class A | 1.85% | 220,400 | $8.5M | Add +63.3% |
| CRNX Crinetics Pharmaceuticals Inc. | 1.67% | 212,010 | $7.7M | New |
| OKUR Onkure Therapeutics Inc. Class A | 1.30% | 1,445,783 | $6.0M | New |
| JBIO Jade Biosciences Inc. | 0.98% | 320,000 | $4.5M | New |
| GHRS GH Research PLC | 0.96% | 315,492 | $4.4M | New |
| ZURA Zura Bio Ltd. | 0.58% | 450,000 | $2.7M | New |
Portfolio Sells Q4 2025 → Q1 2026
Portfolio Buys Q4 2025 → Q1 2026
| CRVS Corvus Pharmaceuticals Inc. | Add +32.6% | 5.82% | +2.61 |
| NERV Minerva Neurosciences Inc. | New | 2.60% | +2.60 |
| CLDX Celldex Therapeutics Inc. | New | 2.18% | +2.18 |
| CRNX Crinetics Pharmaceuticals Inc. | New | 1.67% | +1.67 |
| OKUR Onkure Therapeutics Inc. Class A | New | 1.30% | +1.30 |
| JBIO Jade Biosciences Inc. | New | 0.98% | +0.98 |
| GHRS GH Research PLC | New | 0.96% | +0.96 |
| ZURA Zura Bio Ltd. | New | 0.58% | +0.58 |
| DNLI Denali Therapeutics Inc. | Add +21.0% | 5.05% | +0.06 |
| HNGE Hinge Health Inc. Class A | Add +63.3% | 1.85% | −0.05 |
| VSTM Verastem Inc. | Add +0.4% | 3.62% | −3.69 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $642.6M | CGON, ALMS, SPTX, DNLI, CLDX |
| Q1 2026 | 17 | $460.3M | CGON, ALMS, CNTA, CRVS, DNLI |
| Q4 2025 | 12 | $330.8M | CGON, RAPT, ALMS, CNTA, VSTM |
| Q3 2025 | 12 | $258.9M | CGON, RAPT, CNTA, VSTM, ALMS |
| Q2 2025 | 20 | $177.9M | CGON, CNTA, AKRO, ALMS, RAPT |
| Q1 2025 | 14 | $182.5M | CGON, ALMS, CNTA, RAPT THERAPEUTICS INC, AKRO |
| Q4 2024 | 14 | $224.4M | CGON, ALMS, CNTA, RAPT THERAPEUTICS INC, BCAX |